The major capsid protein L1 of human papillomaviruses (HPVs) has been identified as a promising candidate antigen for a prophylactic HPV vaccine. Since amino acid sequence heterogeneity has been demonstrated for the L1 genes within individual HPV types, nucleotide sequences for L1 were determined from six HPV-18 clinical isolates and the cervical carcinoma cell line SW756 and compared to the published HPV-18 prototype sequence. The sequences were almost identical between the clinical isolates and SW756 but differed markedly from the published prototype sequence. Resequencing the prototype HPV-18 revealed that these differences were due to sequencing artifacts of the prototype HPV-18 sequence archived in GenBank. Thus, the HPV-18 L1 genes seem to display a very high level of sequence conservation. The HPV-18 L1 gene derived from SW756 was expressed in Saeeharomyees cerevisiae and self-assembly of the L1 protein into viruslike particles was demonstrated.
The major capsid protein L1 of human papillomaviruses (HPVs) has been identified as a promising candidate antigen for a prophylactic HPV vaccine. Since amino acid sequence heterogeneity has been demonstrated for the L1 genes within individual HPV types, nucleotide sequences for L1 were determined from six HPV-18 clinical isolates and the cervical carcinoma cell line SW756 and compared to the published HPV-18 prototype sequence. The sequences were almost identical between the clinical isolates and SW756 but differed markedly from the published prototype sequence. Resequencing the prototype HPV-18 revealed that these differences were due to sequencing artifacts of the prototype HPV-18 sequence archived in GenBank. Thus, the HPV-18 L1 genes seem to display a very high level of sequence conservation. The HPV-18 L1 gene derived from SW756 was expressed in Saeeharomyees cerevisiae and self-assembly of the L1 protein into viruslike particles was demonstrated.
Human papillomaviruses (HPVs) are small, non-enveloped DNA viruses that infect cutaneous and mucosal squamous epithelium. From over 70 HPV types described (de Villiers, 1989) HPV-16 and -18 are the causative agents of > 90% of genital warts (condylomata acuminata) and laryngeal papillomas (Gissmann et al., 1983) and HPV-16 and -18 are found in the majority of invasive squamous carcinomas of the cervix (Walboomers et al., 1994) . The progression of HPV-16-associated precursor lesions to cervical cancer occurs relatively slowly and thus has a better chance of being detected at an earlier stage by screening programs. In contrast, HP¥-18 is only rarely found in low-grade cervical intraepithelial neoplasia (CIN) but is highly associated with CIN3 and cervical carcinoma (Arends et al., 1993 ; Kurman et al., 1988) . It has been suggested that these findings reflect a more rapid transit time of HPV-18 lesions through the intraepithelial stage (Arends et al., 1990; Kurman et al., 1988) . In addition, HPV-18 seems to be associated with more aggressively growing cancers * Author for correspondence. Fax + 1 215 652 2142. e-mail Kathrin-Jansen@ Merck.com and poor prognosis of disease (Kurman et al., 1988) . Because of these characteristics of HPV-18-associated disease, a prophylactic vaccine for HPV-18 would be highly desirable. Previous studies using animal papillomavirus models have identified the capsid proteins L1 and L2 as promising targets for immunoprophylaxis (Campo, 1994) . The expression of papillomavirus L1 genes in the baculovirus and yeast expression systems or by using vaccinia virus vectors was shown to result in the assembly of virus-like particles (VLPs) (Christensen et al., 1994; Hagensee et al., 1993; Hofmann et al., 1995; Kirnbauer et al., 1992; Rose et al., 1993 ; Sasagawa et al., 1995; Zhou et al., 1991) which have been demonstrated to induce high-titre virus-neutralizing antibodies (Christensen et al., 1994; Kirnbauer et al., 1992) . Conformational epitopes on these intact VLPs are responsible for eliciting the neutralizing antibody responses (Christensen et al., 1994) . The sequence heterogeneity of L1 genes within one HPV type has been reported (Kirnbauer et al., 1993; Pushko et al., 1994) and in the case of HPV-16 it has been found that amino acid changes within the L1 protein interfered with proper assembly ofVLPs (Kirnbauer et al., 1993) . Also, an ideal HPV-18 vaccine should protect against all HPV-18 0001-3581 © 1996 SGM isolates. We therefore investigated the level of sequence conservation of HPV-18 L1 genes from clinical isolates obtained in the USA. HPV-18 was cloned from the human cervical carcinoma cell line SW756 (Freedman et al., 1992) by digesting total genomic DNA with EcoRI and subcloning DNA fragments of ~ 12kbp into 2EMBL4. The resulting 2 library was screened with a 0.7 kbp HPV-18 L1 DNA fragment which had been generated from SW756 DNA by PCR using oligonucleotide primers designed from the published HPV-18 L1 sequence (Cole & Danos, 1987 ) (GenBank accession no. X05015). A 12 kbp HPV-18-positive clone (# 187-1) was isolated and the complete L1 gene was sequenced using the PRIZM sequencing kit (ABI) and an automated ABI DNA sequencer. The nucleotide sequence from clone #187-1 differed from the published sequence which was originally derived from a cervical biopsy from a Brazilian patient (Boshart et al., 1984) (Table 1) . Most nucleotide changes remained silent at the protein level. However, five nucleotide changes resulted in amino acid changes: three proline to arginine, one threonine to asparagine and one valine to isoleucine conversion. To determine which sequence was more prevalent in clinical isolates, we used an HPV-18-specific PCR assay (H. Z. Markus et al., unpublished results) to screen a panel of six clinical samples (cervical lavages or biopsies; sample #23, 354, 556, 755, 697 and 795) collected in Indianapolis and Philadelphia. Portions of the L1 gene that differed between clone #187-1 and the published sequence were amplified from six HPV-18-positive samples by PCR and sequenced. As shown in Table 1 all clinical isolates closely matched clone # 187-1. Upon resequencing the L 1 gene from the published HPV-18 clone (gift of L. Gissmann), we found that most differences were due to errors in the original sequence that had been submitted to GenBank. These results show that the L1 genes of HPV-18 seem to be more conserved within one geographical region than HPV-16 L1 sequences which have been described (Pushko et al., 1994) .
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We next investigated whether the HPV-18 L1 gene from the SW756 cell line could be expressed in the yeast Saccharomyces cerevisiae. S. cerevisiae offers many advantages for the production of a heterologous protein in terms of scalability and productivity, and the safety of yeast-derived vaccines (exemplified by the hepatitis B vaccines) has been well documented (West, 1993) . The HPV-18 L1 gene was amplified by PCR from clone # 187-1 and subcloned into our yeast expression vector pGAL110 essentially as described previously (Hofmann et al., 1995) . Plasmid p191-6 containing the HPV-18 L1 gene was used to transform S. cerevisiae strain #1558, and clonal isolates were analysed for the expression of the L1 protein as previously described (Hofmann et al., Immunoblots were probed with a polyclonal rabbit anti-L1 serum (Brown et al., 1994) as primary antibody and horseradish peroxidase (HRP)-linked donkey anti-rabbit IgG (Amersham) as the secondary antibody. The blots were processed using the chemiluminescent ECL Detection Kit (Amersham).
1995). Fig. 1 shows an immunoblot of yeast extracts prepared from cells transformed with p191-6. A 60 kDa non-yeast-derived polypeptide having the antigenic properties and electrophoretic mobility expected for the HPV-18 L1 protein could be detected in yeast cells expressing the L1 gene (Fig. 1, lane 2) but not in cells harbouring the control plasmid pGAL110 (Fig. 1,  lane 1 ). An immunoreactive band migrating at a position consistent with a lower molecular mass of ~ 45 kDa was also visible. This most likely represents a proteolytic product of the L 1 protein, since the ratio between smaller and full-length product has been seen to increase during suboptimal purification conditions (data not shown). To investigate whether yeast cells expressing the HPV-18 L1 gene were capable of assembling virus-like particles (VLPs), clarified yeast extracts were prepared and the HPV-18 L1 VLPs enriched by centrifugation through a sucrose cushion for analysis by transmission electron microscopy. VLPs with an average size of ~ 45-50 nm were detected in samples of the L1-expressing yeast cells (Fig. 2) but not in control yeast samples (not shown).
In conclusion, we have documented a high degree of sequence conservation in the HPV-18 L1 genes from US clinical samples and we have shown that the apparent differences from the published HPV-18 L1 ' p r o t o t y p e ' sequence are due to errors in the sequencing of the prototype. Furthermore, we have demonstrated that HPV-18 LI VLPs can be produced in yeast. Future work will determine the irnmunogenicity of highly purified HPV-18 VLPs and their usefulness for a prophylactic anti-HPV-18 vaccine. Fig. 2 . Visualization of HPV-18 L1 VLPs expressed in yeast. Extracts from HPV-18 Ll-expressing yeast were adsorbed to carboncoated copper grids, stained with phosphotungstic acid and examined by transmission electron microscopy. Bar marker represents 100 nm.
